Robert Zamboni - NeuBase Therapeutics Chief Board
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
Insider
Robert Zamboni is Chief Board of NeuBase Therapeutics
| Phone | 412 763 3350 |
| Web | https://www.neubasetherapeutics.com |
NeuBase Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4303) % which means that it has lost $0.4303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9346) %, meaning that it created substantial loss on money invested by shareholders. NeuBase Therapeutics' management efficiency ratios could be used to measure how well NeuBase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.NeuBase Therapeutics currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. NeuBase Therapeutics has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NeuBase Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Assaf Oron | Biomx Inc | 50 | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| FESC MD | NewAmsterdam Pharma | 68 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Pr Sorek | Biomx Inc | N/A | |
| Michael Cooreman | Inventiva Sa | 66 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| FACC Facc | NewAmsterdam Pharma | 65 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| MBA MD | Immix Biopharma | 49 | |
| JD MBA | Immix Biopharma | N/A | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Peter Moesta | Compass Therapeutics | N/A | |
| Inbal BenjaminiElran | Biomx Inc | N/A | |
| Vered MBA | Compass Therapeutics | 53 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
Management Performance
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 |
NeuBase Therapeutics Leadership Team
Elected by the shareholders, the NeuBase Therapeutics' board of directors comprises two types of representatives: NeuBase Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuBase. The board's role is to monitor NeuBase Therapeutics' management team and ensure that shareholders' interests are well served. NeuBase Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuBase Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Branning, CFO Secretary | ||
| Dietrich Stephan, President CEO, Director | ||
| Curt Bradshaw, Chief Officer | ||
| Robert Zamboni, Chief Board | ||
| Alan JD, G Counsel | ||
| Ron MBA, Sr Devel | ||
| Shannon McCarthy, Chief Officer |
NeuBase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuBase Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | (5.83 M) | |||
| Shares Outstanding | 3.75 M | |||
| Shares Owned By Insiders | 13.37 % | |||
| Shares Owned By Institutions | 12.68 % | |||
| Number Of Shares Shorted | 15.57 K | |||
| Price To Earning | (4.17) X | |||
| Price To Book | 0.18 X | |||
| EBITDA | (32.49 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |